The excessing princing by Turing of the old Taxoplasmosis drug has impacted the whole biotech industry, including Celgene. Turing's drug is old and not a product of recent advanced R&D like the new products of Celgene, Giliad, and Amgen. Celgene and its peers commit billions of dollars to research and clinical studies to develop new drugs and treatments. Turing did neither with this drug. Yet, actions of Touring may impact those who are doing the heavy lifting in drug development.
There is a solution to this type of problem, which is not unique just to Touring. Other companies are raising the prices of older drugs, often ones off patent, but single sourced by one company. So, what's the solution. Here's my proposal (hope FDA is listening). Let compounding pharmacies fill perscriptions for these off-patent medicines using standard USP chemical sources. Solve this SPECIFIC problem, rather than penalize the true biotech companies who are committing billions to produce new medications and treatments.